gliobastoma protocol 1c

8/17/2019 Gliobastoma Protocol 1c

http://slidepdf.com/reader/full/gliobastoma-protocol-1c 1/40

GLIOBLASTOMA

A HYPOTHETICAL REGRESSION PROTOCOL

agents

1. Fenofibrate 160g ! one "ai#$ an" % "ai#$ on sat&r"a$ an" s&n"a$

%. 'etfroin ER (00g one "ai#$

). Cieti"ine *00g ! one "ai#$ +,it- t-e etforin/. Ta"a#afi# 10 g ! one "ai#$

(. F#&oetine /0g ! one "ai#$

6. 'ino$#ine 100g "ai#$ 'on"a$ to T-&rs"a$+start % ont-s after start t-e 2rotoo#3. Ce#eoib /00g one a "a$ +,it- t-e ta"a#afi#

*. 4e22ra 5R 1000g ! one "ai#$+a"" a#2roi ai" if nee" seon" agent

7. 8eta g#&an 300g9itain C (00g:: t-ree "ai#$ on fri"a$ sat&r"a$ an" s&n"a$

10. Citr&##ine 3(0g ! % "ai#$ on fri"a$ sat&r"a$ an" s&n"a$11. S&f&ro2-ane 60g ! one "ai#$ +,it- t-e etforin

1%. Li2oi ai" )00g9b:o2#e (0! one "ai#$ +,it- t-e naran

1). Naran /.(g one "ai#$1/. 'e#atonin )g ! one "ai#$ at be"tie

1(. Teo;o#ai"e ! st" "osing a#ong ,9st" ra"iation+<<"o $#o2-os. One "one ,9teo"ar<<<

16. Keytruda to impair PD-1 and help set off regression event 17. Cylcophosphamide ??(parenteral ! (0g9=g > 6 "a$ metronomic dosing to -e#29, regression

1*. C&r&in 2-$tosoe (00g ! % "ai#$ +on fri sat an" s&n ta=e % a2s t-ree ties a "a$

17. A$#oir ! *00g ti" 2o +in-ibit T?O an" I?O

Make sure selenium and vitamin D levels are robust. (upper ! percent o" normalit#$

Some cr#oablation(%elium&argon gas'$o" GBM s%ould be considered due to

immunomodulation induced b# cr#onecrosis and cr#oapoptosis.

-tt2@99,,,.-in"a,i.o9o&rna#s9bri9%01/9%)67)79 "is&sses effets of r$oab#ation

-tt2@99,,,.nbi.n#.ni-.go92&be"9%1%1/%7% discusses immune effects of cryoa!lation

-tt2@99,,,.nbi.n#.ni-.go92&be"9%%)37*/7 r$oab#ation of g#ioas

I suspect Been &st a""ing obo of -ig- "ose curcumin p%#tosome some dose o"

episodic "ludarabine or bid ac#clovir(to "egra"e9i2air I?O beta glucan(po or IM$

Ipilimumab pembrolizumab may result in an improvement in outcomes in GBM.

http://www.hindawi.com/journals/bmri/2014/236939/

http://www.ncbi.nlm.nih.gov/pubmed/21214292




http://www.hindawi.com/journals/bmri/2014/236939/



Simplified Protocol

1. Curcumin Phytosome – 1000mg Tid po2. 1, 1!" PGG Beta Glucan – #mg $%g &M ' (ee% ) # then ' # (ee%s. *luo)etine – "0mg daily po#. *eno+irate – 20mg daily po

-. Tadala+il – 10mg daily po". Celeco)i – #00mg daily po. Cimetidine – /00mg po daily po/. ul+urophane "0mg id po. minocycline – 100mg daily M!Th start 2 months a+ter start the cimetidine310.&pilimuma – standard dosing11. Pemroli4uma – standard dosing12.Cylophosphamide55 maybe55 metonomic dosing – -0mg$%g ' " days ) 1!2 month.1. Temo4olamide and 6adiation – use a standard course o+ chemo$rad1#. Transcranial helium!argon cryoalation55 and radiation to degrade the glio e+ore

neurosurg to remove glio . Be on protocol +or 2 months e+ore remove the glio.1-. 7cyclovir – /00mg id po to inhiit T89 and &8931".8e)amethasone ,%eppra +or the usual reasons.

*or sei4ure control i+ need second agent then add valproic acid.& thin% a cyto%ine storm may e crucial to the regression initiation ecause o+ theimmune changes that accompany the storm. *avorite drin% : (arm re(ed green tea;apan or china version 3 dran% slo(lya sipping tea3 over 20!0 min three times dailyto help lunt &89 issues. 9nly 100mg <GCG asored$cup +rom tongue to end o+esophagus and only 10 = o+ that crosses BBB hence tid.Consider <GCG containing gum as (ell and <GCG containing mints.

http>$$(((.nci.nlm.nih.gov$pmc$articles$PMC22--/$ acyclovir impairs T89 and &89http>$$(((.nci.nlm.nih.gov$pmc$articles$PMC#0-012-$ +udaraine really %noc%s do(n &89

SIMPLEST VERSION

1.Curcumin Phytosome – 1000mg Tid po1/.1, 1!" PGG Beta Glucan – #mg $%g &M ' (ee% ) # then ' # (ee%s1.*luo)etine – "0mg daily po20.*eno+irate – 20mg daily po21.Tadala+il – 10mg daily po22. Met+ormin ?6 – -00mg daily po2. ul+urophane – "0mg id po2#.Cimetidine – /00mg daily po2-. 7cyclovir –/00mg id po2". &pilimuma – standard dosing2. Pemroli4uma – standard dosing2/. Temo4olamide$6adiation – standard dosing

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925358/






GOAL

T-e goa# is to a&se a etabo#i atastro2-e in t-e g#iob#astoa e##s an" sensiti;e t-e tostan"ar" ra"iation an" -eo an" "aage9"ifferentiate9=i## t-e aner ste e##s so no ore

se#f rene,a#B an" a=e t-e i&ne s$ste be rob&st eno&g- to set off a regression eentB

an" initiate an i&ne eor$ eent to 2reent re&rrene ,-en &se" in com!ination "ith standard therapy. I2airing I?O an" T?O are critical to t-e s&ess of t-e 2rotoo#.

Certain as2ets of t-e '?SC "e2#etion 2rotoo# s-o&#" a#so -e#2 2reent re&rreneB -ene its

in#&sion in t-is 2"f.

)*planations

+luo*etine, T-is s-o&#" -e#2 se#etie#$ =i## G8' e##s . It in"&es transebrane a#i& inf#& an"

s&bse>&ent G8' e## "eat- ia interations ,it- A'PARs . It interats ,it- G#&R:1 s&b&nit of t-e

A'PAR an" a&ses ito-on"ria# ebrane "aage an" sets off t-e intrinsi a2o2tosis 2at-,a$s,it- inrease" as2ase )B 7 an" $to-roe C an" PARP. T-e A'PARs are oere2resse" in G8' so

t-e =i##ing is se#etie to G8' e##s. F#&oetine s-o&#" a#so ar=e"#$ "erease e2ression of 'G'T

in G8' an" "isr&2t Nf=8926( signa#ing an" "erease its atiit$ in reg&#ating t-e 'G'T e2ression

in G8' e##s an" sensiti;e t-e G8' to teo;o#ai"e. 'G'T is ino#e" in ?NA re2air.

T%e GBM cell deat% in t%e animal studies -& "luo*etine -as similar -%en t%e# received

temoolamide. and t%e t-o toget%er dramaticall# suppressed tumor gro-t%. T-e obo a#so rea##$

"erease t-e 2ro#iferation ar=er 4i:63. 8$ o2ening t-e 888 a bit B t-e f#&oetine s-o&#" -e#2 inrease brain #ee#s of etforin an" ieti"ine an" &r&in an" fenofibrate.

It is a#so a goo" 2:g#$o2rotein in-ibitor an" so s-o&#" s-o&#" -e#2 to i2roe 888 2enetration of t-e

ot-er agents . Sertra#ine+Do#oft ,i## o2en 888 as ,e##B an" so ,i## bra"$=inin.-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C//631)(9 nie arti#e on f#&oetine effet on G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/((01*19 goo" on f#&oetine an" G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9160((7/(9 nie on se#etiit$ of SSRI on brain t&ors.





http://www.ncbi.nlm.nih.gov/pubmed/16055945/






+eno"ibrate, T-e en" res&#t of fenofibrate in G8' is a etabo#i atastro2-e .Its Ations are rea##$

o2#e B b&t it basia##$ fores t-e G8' to a=e &se of beta oi"ation instea" of g#$o#osis t-en

"aages o2#e I of t-e e#etron trans2ort -ain a=ing it i2ossib#e for t-e G8' to a=e &se of

ETC. ,it- tieB +3% -rs of (0iro' e2os&reB a etabo#i atastro2-e -its t-e G8' e##s .Its effets are se#etie to G8' 2robab#$ bea&se G8' e##s annot onert t-e Fenofibrate to

Fenofibri ai" so t-e Fenofibrate a&&#ates in t-e ito-on"ria# fration an" #ea"s to 2rob#es.

&estion is an ,e get to (0iro' in brain ,it- ora# "osing. e## t-e 2i2erine s-o&#" in-ibit itsg#&eroni"ation an" #ea" to -ig-er ser& #ee#s an" t-e f#&oetine an" ta"a#afi# s-o&#" -e#2 to o2en t-e

88898T8 an" a$be a##o, for better brain 2enetration.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/67/*709 goo" e2#anation of fenofibrate in G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/%7()369 nie e2#anation of t-e e-aniss of t-efenofibrate in"&e" etabo#i atastro2-e in G8' e##s an" ,-$ it is s2eifi to G8' e##s.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)/0700*9 e2#ains -o, fenofibrate an" triggers

8I':e"iate" a2o2tosis in G8' e##s::+-int it ino#es n&#ear trans#oation FoO)A

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/3)((/*9 so fenofibrate re2rogras G8' etabo#i

2at-,a$s in s&- a ,a$ t-at t-e G8' e##s s&ffer fro an energ$ "efiit b&t are sti## fore" to 2ro"&e=etone bo"ies an" ne&roeto"era# aners cannot etabo#i;e =etone bo"ies for t-eir o,n benefit .

T-ose =etone bo"ies an -o,eer at as f&e# for nora# ne&rons an" a#so at as a $to2rotetie

signa#ing o#e&#e for t-e nora# ne&rons

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/1367/69 "is&sses =etone bo"ies as signa#ing

o#e&#es

Sul"urop%ane , s&#f&ro2-ane ations are o2#eB it ,i## in-ibit Nf=8 an" re"&e e2ression of

'G'T. It a#so in-ibits t-e nt9beta:atenin9TCF/ e2ression an" t-is res&#ts in a "erease in iR:%1,it- t-e effet of en-aning t-e =i##ing effet of teo;o#ai"e an" rea##$ re"&ing t-e -anes of

teo;o#ai"e resistane. S&#f&ro2-ane ,-en obine" ,it- etforin s-o&#" a&se aner ste e##s

to #ose t-eir se#f rene,a# abi#it$ an" one #ost B t-at abi#it$ annot be reoere". S&#f&ro2-ane a#soatiates ER419% in a s&staine" fas-ion ,it- t-e res&#t of "o,nreg&#ation of 2 % an" its atiit$ an"

&2reg&#ate" C?//6 g#$o2roteins ,it- oera## effet being a "erease in t-e inasieness of G8'.

S&#f&ro2-ane ,i## a#so &2reg&#ate a#2ain ,it- t-en atiates as2ase 1% ,it- seera# "e#eterio&s"o,nstrea effets in t-e G8' e##s. S&#f&ro2-ane an a#so i2air o2#e III of t-e e#etron

trans2ort -ain an" t-at #ea"s to inrease ROS ,it-in t-e ito-on"ria an" s&bse>&ent "aage #ea"ing

to atiation of as2ase ) an" 7 an" "o,nreg&#ation of 8#%B 8a an" 2() gene atiation. It an a#so

"erease t-e e2ression of ?NA re2air genes. It ,i## a#so in-ibit t-e e2ression of nanog an" ot:/,-i- are =e$ 2#a$ers in se#f rene,a# 2at-,a$s in aner ste e##s. A#so "ereases Deb:1 B G#i:1 an"

G#i:%.

-tt2@99,,,.nbi.n#.ni-.go92&be"91636((%) nie one on s&#f&ro2-ane in G8'




















Metformin: 'etforin o"&#ates an$ 'ANY signa#ing s$stes in aner e##s. Fro an i&ne

stan"2ointB it ,i## enfore e2ression of 'HC I s&rfae antigens in t&or e##s. T&or e##s ,i## aoi""etetion fro $totoi T e##s b$ retrating t-eir 'HC I antigens fro t-eir s&rfae. 8$ enforing

re:e2ression of t-ose 'HC I antigens on t-e e## s&rfaeB etforin s-o&#" -e#2 to a=e t-e t&or

e## ore isib#e to t-e $totoi T e##s. 'etforin ,it- s&#f&ro2-ane s-o&#" "o,nreg&#ate NTs$stes in aner ste e##s an" a&se t-e to 2eranent#$ #ose se#f rene,a# abi#ities. T-e

s&#f&ro2-ane ,i## a#so i2air PGE % 2ro"&tion in '?SCs an"'etforin ,i## a#so =i## g#ioa initiating e##s..

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)6(76619 "is&sses effet on g#ioa initiating e##s.

Note t-e oent t-at etforin is t-e ost #inia##$ re#eant "r&g ever reported for targeting

g#ioa initiating e##s. So&n"s #i=e etforin easi#$ rosses t-e 888 in t-e ne, re2orts.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/)7(10/9 "is&sses e-aniss of etforin in G8

Cimetidine: Cieti"ine at a "ose of *00g ,i## res&#t in an inrease in t-e n&ber of Nat&ra#4i##er e##s an" inrease t-e #ee# of inter#e&=in:% an" ,i## "erease Tregs. Cieti"ine ,i## a&se t-e

"eat- of $e#oi" "erie" s&22ressor e##s ia a2o2toti e## "eat-. '$e#oi" "erie" s&22ressor e##s are

a rea# 2rob#e bea&se t-e$ are a signifiant 2#a$er in t&or "rien i&no:s&bersion an" i&no:easion an" i2air Nat&ra# 4i##er e## f&ntions. T-e$ an ao&nt for &2 to /0 of t-e t&or ass.

T-e$ a#so 2#a$ a #ea"ing ro#e in t-e estab#is-ent of 2reetastati sites basia##$ b&i#"ing a nest for

t&or e##s B t-en 2&tting a ,e#oe -oe beaon in t-at 2reetastati nest to attrat t&or e##s t-at

a$ be ir&#ating in t-e b#oo" . T-e ore $e#oi" "erie" s&22ressor e##s in t-e 2atient ,it- so#i"t&orB t-e ,orse t-e 2rognosisB so an$tie ,e an inatiate or =i## t-ese t$2es of e##sB ,e s-o&#" ta=e

t-e o22ort&nit$. Cieti"ine ,i## a#so "erease t-e rena# t&b&#e seretion of etforin an" inrease

etforin 2#asa #ee#s fro %( to (0 . T-is a=es for a nie ,a$ to inrease etforin #ee#s

,it-o&t an inrease in GI si"e effets fro ora# etforin. Cieti"ine s-o&#" a#so inrease t-e ser&#ee# of f#&oetine an" t-at s-o&#" -e#2 i2air t-e G8' .

Cieti"ine is a#so s$nergisti ,it- Leaiso#e in t-e 2rootion of strong T-1 attrib&tes.

Celebrex: Ce#ebre ,i## res&#t in a "erease in $e#oi" "erie" s&22ressor e##s of a## s&bt$2es. T-e

en" res&#t of e#ebre s-o&#" be -ig-#$ atiate" $totoi T e##s an" better "en"riti e## base"

i&not-era2$ bea&se of re"&e" $e#oi" "erie" s&22ressor e## e2ansion. Ce#ebre ,i## "ereaseo% an" 2ge% ,it-in t-e '?SC s ,it- &#ti2#e benefiia# "o,nstrea effets.

Ce#eoib ,i## a#so "erease in"o#aine %B) "io$genase an" "erease treg e##s.

Lipoic acid and luteolin: T-ese in-ibit IL/. IL( an" IL1) ''P% an" ''P7 . T-ese a&se a

lot of 2rob#es in so#i" t&or -osts. Li2oi ai" basia##$B s-o&#" a&se a 2roton #ea= fro 2$r&ate

"e-$"rogenase to o2e I of t-e e#etron trans2ort -ain an" i2air t-e ,arb&rg effet in t&or e##s.

A#so "ereases ROS +'?SC &se ROS for i&nos&bersion. If ta=e #i2oi ai" t-en a#so nee" to ta=ea b:o2#e itain.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)3(1)*79 nie one #&teo#in in G8'












Beta Glucan: 8eta g#&an s-o&#" a&se a reinstateent of a TH:1 "oinant i&ne s$ste . Its

ations are o2#e. A si2#e ,a$ to t-in= of its ations is to &n"erstan" t-at it re2rogras t-e

i&ne s$ste to e2ress strong an" 2ro#onge" TH:1 s$ste attrib&tes to -e#2 ,it- $totoi T e##an" "en"riti e## f&ntions B o"&#ates seera# =e$ inter#e&=ins an" rea##$ "ereases t-e n&bers of

$e#oi" "erie" s&22ressor e##sB b$ a##o,ing t-e to "ifferentiate into ore at&re e##sB ia t-e"etin:1 ree2torB t-at are t-en ore of an asset to t-e s$ste t-an a -in"rane. It is not absorbe" B b&t

interats ,it- t-e 2e$ers 2at-s aro2-ages in t-e sa## intestine an" t-ose aro2-ages 2i= &2soe of t-e g#&an 2arti#esB 2roess t-e an" t-en -an" t-e off B#i=e a batonB to ot-er i&ne e##sB

,-o t-en notif$ t-e rest of t-e re#eant i&ne tiss&es to re2rogra t-ings to a TH:1 state B bea&se

t-e$ fear t-e beta g#&an is t-e -era#" eent to a nast$ f&nga# infetion an" t-e -&an i&ne s$ste-as eo#e" to -ate f&nga# infetions B it is &st a -a22$ ai"ent t-at t-e sae s$ste +TH:1 B t-at

"ea#s ,e## ,it- f&nga# infetions a#so "ea#s ,e## ,it- t&ors. T-e 1B) 1:6 e2#ains t-e bin"ing an"

bran-ing traits of f&nga# or $east beta g#&ans .T-e ore o2#e t-e bran-ing traitsB t-e better fro an i&no:o"&#ator$ stan"2oint. 8ateria#

beta g#&ans -ae 1B/ instea" of 1B) . T-e Jitain C is in#&"e" in t-e 2rotoo# bea&se it -as a

s$nergisti effet ,it- t-e 8eta g#&an in re2rograing t-e i&ne s$ste. If one -a" t-e I'ersion of beta g#&an :::t-at ,o&#" ,or= >&i=er + I t-in= a$o got t-eirs fro 8iot-era in'innesota.-tt2@99,,,.biot-era.o9inestors9fatKs-eet.-t# t-is &st -as a""ress info on biot-era ::i

t-in= t-at 'a$o got t-eir inetab#e for of 1B) 1:6 beta g#&an for &se in t-eir CLL ono#ona# st&"$

fro biot-era o&t of Egan 'N.

You need robust TH1 attributes to respond to any monoclonal antibody in

any useful way and remember –

monoclonals will really increase L!" le#els and t$at L" t$en $elps to dri#e

resistance to t$e monoclonal% so consider eit$er minocycline or

tolcili&umab or siltuximab as well to deal wit$ t$e L" issues'But cant use minocycline for ( mont$s after start protocol and c$emo'

)altrexone@ Na#treone ,i## inrease at&ration of bone arro, "en"riti e##s an" an" -e#2 s-ift

t-e i&ne s$ste to,ar"s t-e TH1 si"e . It is s$nergisti ,it- t-e #i2oi ai".

At /.( g "ose B t-e na#treone s$ould not a&se o2ioi" ,it-"ra, in t-e 2atient ,-o is on o2ioi" .

-tt2@99,,,.nbi.n#.ni-.go92&be"9%//((336 "is&sses #o, "ose na#treone an" its effets on t-ei&ne s$ste





Melatonin: It -ill %elp maintain IL/ levels -%ic% s%ould %elp maintain a T0 dominant

s#stem. Also '?SCs &se ROS 2ro"&tion as a serio&s e-anis for i&nos&bersion an" so as aer$ rob&st antioi"ant B e#atonin ,i## "iinis- ROS in t-e s$ste.

It ,i## a#so "iret#$ a&gent N4 atiit$. In G8' it s-o&#" sensiti;e t-e G8' to TRAIL e"iate" e##

"eat- an" "erease G#ioa initiating e##s.-tt2@99,,,.nbi.n#.ni-.go92&be"9176)%330 e2#ains TRAIL e## "eat- an" e#atonin

-tt2@99,,,.nbi.n#.ni-.go92&be"9176)%330 "is&sses t-e 2roa2o2toti effets of e#atonin inaner in genera#.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)((1)/% effetieness of e#atonin in in-ibiting HIF:1a#2-a inG8'

-tt2@99,,,.nbi.n#.ni-.go92&be"913))%713 e2#ain ,-$ ,ant to in-ibit HIF:1a#2-a in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%(16)7*7 soe nie effets of e#atonin in G8'"erease"#onogenit$ an" "erease" g#iob#astoa initiating e##s as ,e## as "erease" t&or b&#=.

Minocycline: Minoc#cline -ill in%ibit interleukin12 and do-n regulate t%e e*pression o" t%e

inter#e&=in:6 ree2tor. It a#so ,i## in-ibit atrieta##o2roteinase:% an" 7. T&ors &se ''P% an"

''P7 to en-ane inasion into tiss&es ,-en estab#is-ing etastati sites. Inter#e&=in:6 is t-e

instigator of an$ an$ 2rob#es in aner 2atients B fro a-eia to i&no:s&bersion.

Inter#e&=in:6 ,i## b#&nt t-e TH:1 i&ne res2onse an" en-ane t-e TH:% i&ne res2onse in so#i"t&or 2atientsB so an$tie ,e an in-ibit inter#e&=in:6 in t-e aner 2atient B ,e s-o&#" ta=e t-e

o22ort&nit$. 'ino$#ine -as an$ ot-er ore o2#e ations B b&t fro an i&ne stan"2oint B t-e

aboe is a goo" s&ar$. I#:6 an" '?SCs are t-e ain "riers of a-eia in $ o2inion an" soino$#ine at 100g >"B s-o&#" n&##if$ t-e effet of IL:6 on a-eiaB ,-i#e t-e ot-er '?SC

"e2#eting agents s-o&#" "ea# nie#$ ,it- t-e '?SC iss&es as t-e$ a22#$ to a-eia.

'ino$#ine ,i## a#so profoundly "o,nreg&#ate t-e IL6 ree2tor an" t-e e2ression of GP1)0.It ,i## "erease '#:1 as ,e##. &estion ,9 G8' is ,o&#" t-e ino 2reent transigration of

ne&tro2-i#s aross t-e 888 an" o&#" t-at be a 2rob#e...a#so ,o&#" it b#&nt t-e effet of ieti"ine on

t-e '?SCs sine ieti"ine =i##s t-e ia a2o2tosis.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%1037/%0 ino$#ine in-ibits g#ioa gro,t- b$ in"&inga&to2-ag$.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/(1767(9 "is&sses -o, G8' &ses 27 an" -o,ino$#ine i2airs t-e G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)3/*7179 so ino$#ine ,i## a&se en"o2#asi

reti&#& stress in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%1)%/)(% ino$#ine b#o=s t-e inrease in atri t$2e:1

atri eta##o2roteinase+'T1:''P in g#ioas























-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%31*)*39 e2#ains -o, G#ios e2#oit t-e 'T1:''P

s$ste

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)3/17(*9 nie one t-e ontroers$ of irog#ia#

ations in g#ioas

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)/0*%()9 irog#ia s&22orts t&or e2ansion.e## ino is goo" at "ereasing irog#ia# atiation an" so a$be -e#2s "a2en t-e irog#ia.

-tt2@99,,,.tan"fon#ine.o9"oi9abs910./1619a&to.3.%.1/0/)MaHR0?oL)")"$(0Y(=D7&bG#&DS

(b%0DG72L)8=Di*'C/0'TYL%F1"G*&N$/$LE0'?;E8A'A ino ,i## a&se #ots of

2rob#es for G8's :::::nee" to &se ino$#ine B b&t nee" to fig&re o&t ,-en an" -o,.

$ttp:**onlinelibrary'wiley'com*doi*1+'1++(*i,c'(-.+-*pdf explaines mino

efects on GBM

Citrulline: selecti#ely/ s-o&#" 2roi"e arginine to T e##s ia t-eir arginos&inate s$nt-ase an"

so -e#2s aoi" t-e '?SC in"&e" arginine "e2#etion in"&e" i&nos&2ression of t-e $totoi t

e##s. Ora# Citr&##ine is etabo#i;e" to a &- #esser etent t-an ora# arginine an" t-e '?SCs s-o&#"

not be ab#e to &se itr&##ine as a s&bstrate for arginase:1 B#i=e t-e$ ,o&#" be ab#e to "o ,it- ora#arginine s&22#eentation.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/(1677/9 e2#ains -o, itr&##ine i2roes T:e##f&ntion in Arginine "e2#ete" state

Tadalafil: Ta"a#afi# ,i## in-ibit arginase:1 ,it-in t-e $e#oi" "erie" s&22ressor e## an" i2air its

f&ntion. Arginase:1 "e2#etes arginine an" in"&es arginine "e2#ete" i&nos&2ression of t-e T:e##s.

In G8'B it ,i## a#so inrease 2ereabi#it$ of t-e b#oo" t&or barrier to -eo e"s.

0bstinence from Bisp$enol!0 / MG/ Met$ylparabens and 2arabens and

3ructose: 8is2-eno#:A an" 'SG ,i## s-ift t-e i&ne s$ste to,ar"s TH:% e2ression. TH:%s-ifting is one of t-e i&nos&bersion too#s so#i" t&ors &se to aoi" "etetion. 'et-$#2arabens an"Parabens ,i## inrease e2ression of 'tor signa#ing s$ste an" i2air t-e e2ression of P() signa#ing

s$ste T,o t-ings one ,o&#" never ,ant to "o in a so#i" t&or bea&se it ,i## a=e t-e t&or ore

aggressie.8is2-eno#:A an" 'et-$#2arabens an" Parabens are a#so enoestrogeni agents an" so one o&#"

oeroe t-e 2rotetion of antiestrogeni t-era2ies ,it- een o"erate e2os&res. Fr&tose is t-e

s&gar t&ors 2refer. T-e$ gro, faster ,-en e2ose" to fr&tose. For t-e 2rotoo#B &st ass&e8is2-eno#:A is 2resent in a## 2#asti an" eta# an" a#&in& foo" an" beerage ontainers an" on a##







http://www.tandfonline.com/doi/abs/10.4161/auto.7.2.14043#aHR0cDovL3d3dy50YW5kZm9ubGluZS5jb20vZG9pL3BkZi8xMC40MTYxL2F1dG8uNy4yLjE0MDQzQEBAMA


http://onlinelibrary.wiley.com/doi/10.1002/ijc.28908/pdf








http://onlinelibrary.wiley.com/doi/10.1002/ijc.28908/pdf




t-era# reei2ts an" "&2#iate -e=s an" in ost -an" #otions an" abstain fro e2os&re to t-ese

t-ings. A#soB for t-e 2rotoo#B si2#$ ass&e t-at et-$#2arabens an" 2arabens are

in a## s-a2oos9osetis an" -air on"itioner agents an" ge# base" &n"er ar "eo"orants &n#ess t-e

bott#e states ot-er,ise.

4itamin 5: Jitain is a o2#e i&noo"&#ator$ agent . It is a#so a aster reg&#ator of $

signa#ing s$stes an" $ is a rea# 2rob#e in G8' .

It is a#so =e$ 2#a$er in atiation of T:e##s. &st a=ing ertain it is ,it- in t-e

nora# range+&22er 10 2erent s-o&#" s&ffie.Jitain ? ations are o2#e . e "o not ,ant 2rofo&n" "efiien$ state

bea&se of inrease" $ iss&es B b&t t-ere a#so is "ata t-at rob&st #ee#s a$ s-ift t-e i&ne s$ste

to,ar" t-e TH% s$ste an" t-at ,o&#" be &n"esirab#e in t-is 2rotoo# as ,e 2refer strong TH1attrib&tes in t-e 2rotoo#. A#so "erease ROS. Ai for a ser& #ee# of 60:30.

Gien t-at I?O+in"o#eaine %B): "io$genase is t-e a&se of tr$2to2-an "e2#ete" i&nos&22ression

an" is &2reg&#ate" in so#i" t&or -ostsB an" gien t-at EGCG an" reseratro# an" &r&in are I?O

in-ibitorsB t-e faorite "rin= s-o&#" be green tea+-ina9a2an ariet$ an" go#"en i#=+&r&in"ran= ,ar an" s#o, oer )0 in bi" an" t%e "avorite treat s%ould be )G3G in t%e gum or mint

(senc%a brand$ for as EGCG is ain#$ absorbe" fro s&b#ing&a# to t-e en" of eso2-ag&s .

A#so gien t-at f#&"arabine "egra"es I?OB a$ ,ant to onsi"er t-at as ,e##.I?O ,i## a=e it i2ossib#e for t-e i&ne s$ste to oat t-e so#i" t&or ,it- o2#eent an" an

a#so -ange C?* T:e##s into a T:reg e## 2-enot$2e aong ot-er ba" t-ings so it nee"s to be

i2aire" 9"e2#ete"

One annot oerstate t-e i2ortane of t-ese I?O ations on t-e aintenane of t-e so#i" t&orsi&ne 2rii#ege. For an$ -ane of regression in G8'B IDO must be impaired and depleted at t-e

f&ntiona# B transri2tiona# B an" reg&#ator$ #ee# as ,e## a&sing its "egra"ation an" &r&in B egg

an" f#&"arabine an" reseratro# s-o&#" -e#2 a-iee t-at goa#. 'et-$# tr$2to2-an is anot-er -e#2f&#agentB b&t t-e 2rotoo# ,as reate" to a=e &se of agents easi#$ obtainab#e an" et-$# tr$2to2-an is

not easi#$ obtainab#e.

3urcumin, C&r&in ,i## -e#2 enfore "ifferentiation of g#ioa initiating e##s an" re2resses t-eir se#f rene,a# abi#it$ b$ initiating "ifferentiation asa"es ,it-in t-e g#ioa initiating e##s.

It ,i## a#so "rie t-e g#ioa initiating e##s into a&to2-ag$ an" "ereases t-eir #onogeni abi#it$.It ,i## sensiti;e t-e G8' to teo;o#ai"e t-era2$ ia i2roe b#o=a"e of A4T9Tor atiit$ .

It a#so inrease" ROS 2ro"&tion ,it-in t-e G8' e##s. C&r&ins abi#it$ to "erease G8' e##

s&ria# is 2() an" as2ase in"e2en"ent an" is base" on its in-ibition of AP:1 an" Nf=8 ia 2reentionof onstit&tie N4 an" A4T atiation. It a#so s&22resses $#in:?1BP:NF=8B 8#5LB P:A4TB JGEFB

an" a&gents t-e atiit$ of erai"es. C&r&in "oes so an$ t-ings B better to a"" a #in= to a er$

nie arti#e on &r&in e-aniss in aner e##s. C&r&in ,i## -e#2 restore t-e i&ne s$ste B



restores t-e C?/9C?* T:e## 2o2&#ationsB reerse t-e t$2e % $to=ine biasB re"&e Treg e## 2o2&#ations

an" s&22ress T:e## a2o2tosis. Prob#e is bioaai# iss&es ! t-e 2-$tosoe ersionB -ig- "oseB an"

2i2erine ,i## -e#2 ,it- t-is iss&eB b&t got to be =in"a aref&# ,it- 2i2erine as an inrease #ee#s of

ot-er agents an" t-at an be -e#2f&# or not -e#2f&# "e2en"ing on t-e agent affete".T-at is ,-$ ta=e &r&in92i2erine obo on t-e ,ee=en"s on#$.

C&r&in is a#so a goo" in-ibitor of in"o#aine %B) "io$genase !

Indolamine /45 dio*#genase is 36ITI3AL to GMB "or immunosubversion.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%3(*1%19 t-is arti#e e2#ains in great "etai# t-e

ario&s e-aniss &r&in a=es &se of to i2air so#i" t&or.

-tt2@99,,,.nbi.n#.ni-.go92&be"916/166009 ore &r&in e-aniss in g#ioas

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/67100/9 &r&in a#so affets iR:%1 ,it- serio&s

benefiia# "o,nstrea effets.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/1((63/9 iR:%1 is a rea# 2rob#e -i#" in G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/60)73)9 &r&in restoration of t-e i&ne s$ste

t-is is seriously nice article.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/00)%%(9 e2#ains -o, &r&in reerses T:e##

re#ate" i&ne "$sf&ntion in t-e t&or bearing -ost. JERY GOO? ARTICLE

-tt2@99,,,.-ea#t-$an"nat&ra#,or#".o9t&reri:go#"en:i#=:rei2e9 s-o,s -o, to a=e &r&in 2aste an" -o, to a=e go#"en &r&in i#= ! t-e oon&t oi# ,i## "isso#e &r&in +10g9# an"

bea&se oon&t oi# is a e"i& -ain trig#$eri"e B s-o&#" get absorbe" 2assie#$ an" "iff&se#$

a#ong t-e gi trat....so a$be one ,a$ to i2roe bioaai# of &r&in+ >&estion is ,o&#" a""ing %0g 2i2erine -e#2 ,it- absor2tion of go#"en i#= &r&in.

Pembrolizumab , t%is is a monoclonal to t%e programmed deat% receptor1 . It s-o&#" i2air t-ef&ntion of P?:L1 an" -e#2 ,it- i2air t-e i&nos&bersion G8' &ses to aoi" t-e i&ne

s$ste.

)G3G, Egg ,i## in-ibit in"o#aine %B) "io$genase at a f&ntiona# #ee# an" at a transri2tiona#

#ee#. It ,i## in-ibit t-e en"o2#asi reti&#& -a2erone GRP3* . GRP3* ontrib&tes toteo;o#ai"e resistane an" is a 2ros&ria# o2onent of t-e en"o2#asi reti&#& stress res2onse

s$ste an" is &2reg&#ate" in G8'. Egg in-ibits t-e ste e## -arateristis of g#ioa initiating e##s.

An" -as s$nergisti effet ,-en obine" ,it- teo;o#ai"ein t-e ania# st&"ies. Egg a#so "o,nreg&#ates 2:g#$o2rotein e2ression in-ibits ne&ros2-ere foration an" e## igration

#eaes PARP an" "o,nreg&#ates 8#% an" IL6B IL*B'CP:1 ''P% an" ''P7 an"

RANTESBt-iore"oin:1 an" er&#o2#asinB 2:A4T an" in"&es9a&gents Trai# e"iate"a2o2tosis in t-e e## o"e# an" a#so "ereases t-e inasieness of g#ios.












http://www.healthyandnaturalworld.com/turmeric-golden-milk-recipe/







http://www.healthyandnaturalworld.com/turmeric-golden-milk-recipe/



-tt2@99,,,.nbi.n#.ni-.go92&be"9%1%(3%(7 "is&sses egg effet on ER.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%((//630 egg s$nergisti effets ,it- antianer agents

-tt2@99,,,.nbi.n#.ni-.go92&be"91031713/ egg in-ibits 2% an" 27 in g#ios.

-tt2@99,,,.nbi.n#.ni-.go92&be"911*()*7) e2#ains effet of egg on ''Ps

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%31*)*39 rea## t-at G8's e2#oit t-e ''P s$ste toe2an" an" ina"e tiss&e so goo" i"ea to in-ibit t-at abi#it$ if one an.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/)*/3079 goo" one egg effets

-tt2@99,,,.nbi.n#.ni-.go92&be"9137/%711 "is&sses GRP3* 98iP as a target in t-e &nfo#"e"

2rotein res2onse s$ste :::i2air it an" $o& inrease effetieness of teo;o#ai"e an" (:F.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)3%1/109 goo" arti#e for an e2#anation of -o, egg

interats ,it- GRP3*......

-tt2@99,,,.nbi.n#.ni-.go92&be"91*7/*167 "is&sses -o, egg a&gents trai# e"iate" e##"eat- in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%1/37//1 er$ nie one on effets of egg in g#ioas ::

ACYCLOJIR@ In-ibits T?O an" I?O an" rosses t-e 888.

-tt2@99ne&roinf#aation.bioe"entra#.o9arti#es910.11*6913/%:%07/:3:// a$#oir

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%7%()(*9 t-e 2 ersion














http://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-7-44













http://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-7-44




refs

[email protected]&bs.org9ontent9%*91%9%0(1.f&## 2ro#onge" #o, "ose teo;o#ai"e

-tt2@99,,,.nbi.n#.ni-.go92&be"9%(/)/)*7 nie one on 2ro#onge" &se of teo;o#ai"e "is&sses 'G'T et-$#ation iss&e as ,e## ::::,e## a#2roi ai" is a goo" H?AC in-ibitor

-tt2@99,,,.nbi.n#.ni-.go92&be"91(/**)%( "is&ses statin &se in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%00//(76 basia##$ "ont &se -ig- "ose statin in G8'statins

-ae o2#e effets in G8' an" nee"s ore st&"$ before &se.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)3110*%9 e2#ains o2#eit$ of statin effets on

G'8

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)*7)/6*9 nie one on s$nergis bet,een e#ebre an"f#&astatin in astro$toa

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)303033 e2#ains atroastatin abi#it$ to "erease G8'inasion

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)16)6139 "is&sses 2ossibi#it$ of &sing statins as

antianer agents in G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)3((0309 nie one on in-ibitors of inasion in G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C))3)%(09 a#2roi ai" an sensiti;e t-e G8' to

teo;o#ai"e ia "o,nreg&#ation of 'G'T e2ression. e## JPA ations are o2#e in G8' B b&t

if nee" a seon" sei;&re e" t-en a$be a"" a#2roi ai".

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/3)66139 targeting a&to2-ag$ -e#2s sensiti;e to

teo;o#ai"e

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/3)66139fig&re9Fig19 nie "iagra of resistanee-aniss to teo;o#ai"e

http://jco.ascopubs.org/content/28/12/2051.full
















http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736617/figure/Fig1/

http://jco.ascopubs.org/content/28/12/2051.full














-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/3)66139fig&re9Fig%9 nie "iagra on o"&#ation of

a&to2-ag$

-tt2@99,,,.nbi.n#.ni-.go92&be"9%(6*166*9 "is&sses t-e s$nergis bet,een teo;#ai"e an"

-#oro>&ine+-#oro>&ine in-ibits a&to2-ag$

-tt2@99,,,.nbi.n#.ni-.go92&be"9%((%*6)( -#oro>&ine in-ibits ito-on"ria# a&to2-ag$

-tt2@99,,,.nbi.n#.ni-.go92&be"9%%3**36/9 "is&sses targeting 'G'T in g#os ::: ,e## f#&oetine

an" a#2roi ai" i2air 'G'T

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/(06)739 effet of "eat-asone on i&ne sit&ation

in G8' :::basia##$ best to get ,ean off of t-e "eaet-asone 4

but SLO7L8 so as to avoid adrenal crisis

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/30(*3(9 a=es t-e arg&ent t-at t-e i&ne"istortions a$ -ae been ore fro ra"iation t-an t-e "eaet-asone.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/30(*369 res2onse to t-e aboe arg&ent. e##B it is a

o2#e atter...an" t-e effets of "eaet-asone are er$ o2#eB ..b&t a$be best to s#o,#$ ,eanfro t-e "eaet-asone if ab#e Q.

-tt2@99,,,.nbi.n#.ni-.go92&be"913*0/3/% e2#ains -o, si#ibinin an reoer trai# sensitiit$ in

Trai# resistant g#ioas..

-tt2@99,,,.nbi.n#.ni-.go92&be"91*13%)17 &st an interesting one on Trai# an" arseni trioi"e in

g#ioas

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C//7%0*09 i&nos&22ressie e-aniss in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%63/*067 e-aniss of &r&in in G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)1%*/339 e2#ains beta g#&ans
































-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/17*7)/9 "is&sses e-aniss of g#ioa foration

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)7%/(/)9 "is&sses t-e effet of interittent

etronoi "osing on t-e i&ne s$ste in G8' !t-e$ &se" 2arentera# $#o2-os2-ai"e at

1/0g9=g in t-e ania# st&"$ ,it- nie effets.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/16%*109 "is&sses &se of etronoi "osing on an

eer$ 6 "a$ s-e"&#e ,or=s t-e best to set off e*tensive t&or regression an" sti&#ate ario&s

i&ne res2onses.... ,e## soe re#a2se" oer tie ! I t-in= t-at &st 2oints to nee" for a""itiona#i&ne o"&#ating agents an" '?SC "e2#etion agents #i=e beta g#&anB ieti"ine.e#ebreB

ia#is..et as ,e## as agents to eit-er =i## or stri2 t-e g#ioa ste e## of t-eir se#f rene,a#

abi#it$+s&f&ro2-ane an" etforin.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C(0*(*)9 t-is arti#e s&22orts t-e i"ea of b$stan"er

effets of $#o2-os2-ai"e an" i2ortane of a"o2tie i&nit$ in2&t .

-tt2@99,,,.nbi.n#.ni-.go92&be"913%((%** anot-er goo" one on t-e i2ortane of t-e $to=ine

stor "&ring t-e rebo&n" 2-ase after "r&g in"&e" #$2-o"e2#etion.

It i2roe" a"o2tie#$ transferre" i&ne e##s.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%61)3/0% etronoi $#o2-os2-ai"e in"&e" era"iation

of #arge i2#ante" g#ioa an" set off i&ne eor$ eent ! I t-in= t-e$ &se" t-e >6 "osing at1/0g9=g. Tumor regression leading to tumor ablation -as seen a"ter use o" several c#cles.

Reetion of t-e t&or re:-a##enge ,as assoiate" ,it- inrease in $totoi T e##s onsistent ,it-

t-e in"&tion of s2eifi #ong ter C"* T:e##s antit&or eor$ + ::a#so rea## t-at t-e etforins-o&#" -e#2 a=e t-e C?* eor$ e##s #ie #onger b$ basia##$ re2rograing t-eir etabo#is.

A#so rea## t-at t-e en" res&#t of e#ebre should be ore -$2eratiate" $totoi T:e##s.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C//*(*%69 -ere is t-e P'C ersion of t-e aboe arti#e.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/63*30)9 nie e2#anation of in"o#aine%B)

"io$genase e-aniss in so#i" t&or esa2e strategies.Yo& rea##$ #$%& to "e2#ete in"o#aine %B) "io$genase if ,ant regression eent to o&r

























-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/1*%)(09 so ,-en target I?OB P?:L1 an" CTLA:/ a##

t-en ania#s ,it- G8' t&rne" into #ong ter s&riors... I t-in= t-is s&22orts t-e t-in=ing t-at

&#tie-anisti a22roa- to G8' is essential to era"iation Bregression an" i&ne eor$.

-tt2s@99en.,i=i2e"ia.org9,i=i9I2i#i&ab nie ,i=i e2#anation of i2i#i&ab as a ono#ona# toCTLA:/

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/10(*319 anot-er goo" on ,-at -a22ens ,-en "e2#etein"o#aine %B) "io$genase...... it -e#2s a #ot.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)67*(%)9 "is&sses t-e ritia# nat&re of I?O in t&ori&nos&bersion

-tt2@99,,,.nbi.n#.ni-.go92&be"9%1611*3% interesting one on i&ne effets on

$#o2-os2-ai"e an" aines

-tt2@99,,,.nbi.n#.ni-.go92&be"91*(/0*%3 e2#ains soe e-aniss of $#o2-os2-ai"ei&ne o"&#ation :::: I t-in= it s-o&#" be an agent &se" in t-e 2rotoo#.

-tt2@99,,,.nbi.n#.ni-.go92&be"91((*(7*1 "is&sses t-e innate i&ne s$ste an" G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9177//76) "is&sses t:e## anerg$ an" ot-er 2rob#es in G8'

i&ne resistane..... a=es one t-in= abo&t Effets of I?OB ARGINASE:1 B '?SCs an" $steine

tr$2to2-an an" arginine "e2#etion effets on t-e CNS t:e##s.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%1611*3%9 "is&sses t-e i&noo"&#atro$ effets of$#o2-os2-ai"e as re#ates to &se of aner aines.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%11/*/*6 "is&sses effet of $#o2-os2-ai"e on TH13 s$ste



https://en.wikipedia.org/wiki/Ipilimumab












https://en.wikipedia.org/wiki/Ipilimumab











-tt2@99,,,.nbi.n#.ni-.go92&be"9%)/%/0%/ beta g#&an effet on '?SCs

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%7306%39 ora# beta g#&an "oes -e#2 antit&or

i&nit$

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)/317(/9 ore abo&t beta g#&an

-tt2@99,,,.nbi.n#.ni-.go92&be"913/0310% "is&sses GITR ::: beta g#&an an" naran bot- affet

GITR

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/10/77(9 obining P?L1 in-ibition an" GITR

triggering in t-e aner -ost

-tt2@99,,,.nbi.n#.ni-.go92&be"9%017*)%3 "ereasing Tregs -e#2s i&ne s$ste

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)/1)%(19 "is&sses o"&#ation of gitr in aner

t-era2$

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C//631)(9 "luo*etine causes apoptosis in GBM

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)/66(109 "eno"ibrate kills GBM

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)/66()79 anot-er one on fenofibrate

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/%7()369 "is&sses t-e e-aniss of t-e etabo#iatastro2-e in"&e" b$ fenofibrate in G8'::: t-is a great arti#e

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%71%%/39 ore on t-e e-aniss of fenofibrate




































-tt2@99,,,.nbi.n#.ni-.go92&be"9%//7)(36 anot-er er$ goo" one on fenofibrate &se in G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/6((%/%9 etforin targets aner ste e##s in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%6/)1)37 "is&sses ore e-aniss of etforin in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%/76(/1) etforin ,it- sorafenib =i##s G8' ste e##s

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/)7(10/9 etforin a=es teo;o#ai"e an"ra"iation ore effetie in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%6)%767( etforin "oes inf#&ene s&ria# in G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/%7/)*19 nie one on re2ositioning etforin as

antit&or agent in G8' ste e##s

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)(30(0/9 anot-er goo" one etforin in G8'#ear#$ it -as effets

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)(*3/(09 sorafenib an" G8' ste e##s !an" "e2#etes

t-e :::good because current treatment "or GBM enric%es t%e tumor -it% cancer stem cells +avery bad thing)

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%*(%/639 sorafenib =i##s G8' e##s

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/%6*10/9 Re?o ieti"ine as an antianer agent

-tt2@99,,,.nbi.n#.ni-.go92&be"916(76%1* ieti"ine &se in G8'

-tt2@99 ,,,.nbi.n#.ni-.go92&be"91(*31(1/ ieti"ine obine" ,it- teo;o#ai"e





































-tt2@99astro$toao2tions.o9re2&r2ose":"r&gs9 &st interesting

-tt2@99,,,.nbi.n#.ni-.go92&be"9<terieti"inean""san"fas ieti"ine =i##s '?SCs

-tt2@99,,,.nbi.n#.ni-.go92&be"9%()0)(/1 2"e ( inb-ibitors obine" ,it- e#ebre

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/)7*)1/9 e#eeob an" 2"e( in-ibitors

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%6)%((19 2"e( in-ibitors inrease b#oo" t&or barrier

2ereabi#it$ for -eo in G8' ...recall that !rady'inin also opens the :::

-tt2@99,,,.nbi.n#.ni-.go92&be"9%/6(10)3 interesting

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%11*16)9 ta"a#afi# i2airs '?SC f&ntion

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/)%%*7(9 ta"a#afi# re"&es '?SC an" Treg e##s

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/66%/169 "is&sses '?SCs

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/66%/169 "is&sses i&ne s$ste an" '?SCs

-tt2@99,,,.nbi.n#.ni-.go92&be"9%6300/61 t:e## an" '?SC interats

-tt2@99,,,.nbi.n#.ni-.go92&be"9%6(/6/() #ong ter regression of G8' in ania#s ,it-

=e$tr&"a

-tt2@99,,,.nbi.n#.ni-.go92&be"9%6(3*6%) "is&sses '?SC in G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C//*(*%69 interesting arti#e

http://astrocytomaoptions.com/repurposed-drugs/

http://www.ncbi.nlm.nih.gov/pubmed/?term=cimetidine+and+mdsc+and+fas



















http://astrocytomaoptions.com/repurposed-drugs/

http://www.ncbi.nlm.nih.gov/pubmed/?term=cimetidine+and+mdsc+and+fas















-tt2@99,,,.nbi.n#.ni-.go92&be"9%/%1(%*) '?SCs in G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)(6/%/%9 '?SC an" t&ors re#ations-i2

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%7/06769 =e22ra a=es G8' ore sensitie toteo;o#ai"e

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/6637/19 a#2roi ai" in G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C1*((%0/9 e2#ains -o, -e"ge-og ontro#s CSCs

-tt2@99,,,.nbi.n#.ni-.go92&be"9%66/*1%) s&#f&ro2-ane reerses T'D resistane

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%7%*67%9 "is&sses t-e g#i9nanog92() ne,or= an" its

effets on aner ste e##s.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%(771)3% s&#f&ro2-ane i2roes T'D t-era2$

-tt2@99,,,.nbi.n#.ni-.go92&be"9%06))()7 "is&sses t-e effet of iR:%1 on T'D resistane

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)7)*3((9 s&#f&ro2-ane in-ibits G8' inasion

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C//71(6)9 s&#f&ro2-ane effet on ROS 2ro"&tion

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)/6100)9 "is&sses s&#f&ro2-ane abi#it$ to o"&#ate

se#f rene,a# in aner ste e##s....it is a soni -e"ge-og in-ibitor

-tt2@99,,,.nbi.n#.ni-.go92&be"9%%/06777 "is&sses soni -e"ge-og signa#ing in G8'





































-tt2@99,,,.nbi.n#.ni-.go92&be"9%)(///%) "is&sses t-e ro#e of t-e g#i 2roteins in G8' :::,e##

s&#f&ro2-ane o"&#ates G#i 2roteins.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%%11/1// soni -e"ge-og an" g#i interations...s&#f&ro2-ane

o"&#ates Nanog an"

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)1%7%(3 s&#f&ro2-ane effets on soni -e"ge-og

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%7%*67%9 so nanog is essentia# to aner ste e##s in

G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"91636((%) &#ti2#e e-aniss in &se ,it- s&#f&ro2-ane inG8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%6*()//3 "is&sses effets of "ietar$ 2-$to-eia#s in aner

ste e##s

-tt2@99,,,.nbi.n#.ni-.go92&be"9%//6)%7* &r&in esses ,it- se#f rene,a# 2at-,a$s in CSCs

::: f$i !so "oes s&#f&ro2-ane

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%*6%1))9 "is&sses e-anis of s&f&ro2-ane inaner ste e##s :::t-e$ #ose abi#it$ of se#f rene,a#.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%0()06*3 s&#f&ro2-ane sorafenib =i##s aner ste e##s.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)66116%9 &st interesting

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)(00)%/9 s&#f&ro2-ane an" PGE% s$nt-ase

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)0131)7 PGE% effet on '?SCs






























-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)%13)(%9 PGE% CO5% #ots of '?SCs so goo" to

rea## t-at e#ebre ,i## in-ibit o% an" PGE% an" s&#f&ro2-ane ,i## in-ibit PGE% s$nt-ase ,it-in t-e

'?SC

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/)6*1()9 nie one on '?SCs

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C10670369 regression e-aniss

-tt2@99,,,.nbi.n#.ni-.go92&be"911)1))369 interesting

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/017*7(9 9I3) one on MDS3s an" ,a$s to i2air

t-e in aner 2atient.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%0)**37(9 (:F ,i## =i## '?SCs

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%*0(0(39<re2ort#assi t-is is ,-$ s&22#eent ,it-

$steine

-tt2@99o&rna#s.2#os.org92#osone9arti#e<i"10.1)319o&rna#.2one.00/73// er$ goo" one on effet of

s&#f&ro2-ane on '?SCs

-tt2@99,,,.nbi.n#.ni-.go92&be"91((6*%*7 e2#ains ,-$ itr&##ine is nee"e".

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C//300//9 "is&sses soe antit&or effets of #i2oiai" .

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)66(%7*9 e2igeneti effets of &r&in in G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/6%3%))9 e-aniss of &r&in in G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)6/0((*9 nanofor&#ations of &r&in

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%3(*1%19 &r&in an" aner











http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805057/?report=classic

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0049744



















http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0049744









-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/60)73)9 &r&in an" its i&ne effets

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/00)%%(9 &r&in reerses t-e t:e## e"iate"

i&ne 2rob#es in t&or -ost

-tt2@99,,,.nbi.n#.ni-.go92&be"9%/16(%71 &r&in e-anissin g#ioas

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%*6%*639 &r&in effets on ste e##s

-tt2@99,,,.nbi.n#.ni-.go92&be"9%11)**30 &r&in an" A4 an" STAT) in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"917)06)3% STAT) in-ibition in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%66)3*/6 &r&in &se in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%6%3()73 targeting G8' ,it- 2-$to-eia#s

-tt2@99,,,.nbi.n#.ni-.go92&be"9%6%)7617 &r&in an" T'D

-tt2@99,,,.nbi.n#.ni-.go92&be"9%(37%)*( &r&in sensiti;es G8' to ra"iation.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%((/%0*) a goo" one on T'D9&r&in obo

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)6)(7069 nie one on reseratro#

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)%/*%079 b#o=ing nf=b -e#2s

-tt2@99,,,.nbi.n#.ni-.go92&be"9%1/%)%0% b#o= nf=b an" it -e#2s




































-tt2@99,,,.nbi.n#.ni-.go92&be"9%10/0311 nf=b in-ibitors

-tt2@99,,,.nbi.n#.ni-.go92&be"9%61(133( Let:3 an" '$ are rea# iss&es in G8' :::t-e$ ess

,it- g#&ose etabo#is

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)377**/9 "is&sses t-e signa#ing s$stes t-at are

esse" &2 in g#iob#astoa

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%7/06379 "is&sses Tor atiit$ in G8' an" ,a$s toi2air it ::: rea## t-at etforin is a 2rett$ goo" Tor in-ibitor

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)1*0*739 "is&sses a2= as a target in G8':::etforin affets A'P4 b&t #iite" b$ 888 2enetration !nee" to see if 2:g#$o2rotein in-ibition

,o&#" i2roe etforin 2enetration aross t-e 8888

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)%6*1*69 "is&sses PGP iss&es at 888

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/600/**9M86% "is&sses ario&s ,a$s to in-ibit 2g2

eff#& at 888::::#oo=s #i=e f#&oetine is a o"erate 2g2 in-ibitor. goo" reason to be on 2ro;a.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)33)6319 "is&sses era2ai# as 2g2 in-ibitor.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%*(66319 nie arti#e on 2"e( in-ibitors effet on 888

in t&ors !inrease 2ereabi#it$ of 888 in brain t&or b&t not in nora# brain tiss&e...t-at is a goo"

t-ing.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%6)%((19 "is&sses si#"enafi# an" bra"$=inin as agents

to o2en t-e 888.

-tt2@99,,,.nbi.n#.ni-.go92&be"91%/)*(%/ "is&sses ,a$s to affet t-e 888











http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600488/#B62






















-tt2@99astro$toao2tions.o9t-e:b#oo":brain:barrier9 "is&sses 888 an" f#&oetine an" era2ai#

:11probabl# all GBM "olks s%ould be on :roac ;!mg dail# and i" 0T9 t%en verapamil as -ell

-tt2@99,,,.nbi.n#.ni-.go92&be"917*37)*% "is&sses t-e "$sreg&#ate" signa#ing s$stes in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"91761**(% ro#es for g#&taate ree2tors in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%(*1*))7"is&sse i&ne easion in aner:::I t-in= it s&22orts

notion t-at TH1 s-iftingB inrease N4 e##s ,o&#" -e#2:::soe t-e bioaai# iss&es ,it- &r&in an beoeroe ,it- t-e P-$tosoe ersion of &r&in an" a#so b$ ta=ing 2i2erine ,it- t-e &r&in.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%%)%3**% s&22orts t-e i"ea t-at "e2#eting T:reg e##s

-e#2s+ rea## t-at ieti"ine ,i## "erease Tregs

-tt2@99,,,.nbi.n#.ni-.go92&be"91(0)%(7(9 "is&sses t:e## eor$ effets

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/63/0009 "is&sses etforin abi#it$ to reerse

,arb&rg effet

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)6107**9 e2#ains -o, et-$#ene b#&e reerses t-e,arb&rg effet in G8' e##s.

-tt2@99,,,.nbi.n#.ni-.go92&be"91%13%(/1 "is&sses b#o=a"e of A'PA ree2tors in G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/%%66639 "is&sses "r&g o=tai# for G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%06(%3%/ anot-er one on "r&g o=tai#s for G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%%(6031%9 "is&sses artes&nate in G8'

http://astrocytomaoptions.com/the-blood-brain-barrier/




http://www.ncbi.nlm.nih.gov/pubmed/25818339discusse















http://www.ncbi.nlm.nih.gov/pubmed/25818339discusse











-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)*1)/139 "is&sses "r&g :"r&g interations in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%%6)71(79 "is&sses G'8 i&nos&bersion

-tt2@99,,,.nbi.n#.ni-.go92&be"9%/(*%/)% tregs 2#a$ big ro#e in G8' i&nos&bersion.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)(00/)/9 In"o#aine %B) "io$genase is a -&ge

2rob#e in t-e G8' i&ne s$ste ::: ,e## &r&in is a er$ goo" in-ibitor of I?O an" egg is ao"erate in-ibitor of I?O. F#&"arabine ,i## "egra"e I?O.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%66)6)*7 a=es a goo" arg&ent to in-ibit I?O in G8' 2atient.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%(0(/)0) "is&sses tr$2to2-an etabo#is in G8'

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/6/1(%%9 in"o#aine %B) "io$genase 2#a$s a

CRITICAL ro#e in G8' i&nos&bersion.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)1//%7) 'ST INHI8IT I?O

it is t-e a&se of too an$ iss&es.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)07011* "is&sses tr$2to2-an atabo#is in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%61/0%/% "is&sses -o, aner re2rogras t-e i&ne s$ste.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/0(01%(9 e2#ains -o, f#&"arabine i2airs I?O

-tt2@99,,,.nbi.n#.ni-.go92&be"91703(0139 &r&in in-ibits I?O

-tt2@99,,,.nbi.n#.ni-.go92&be"913%301/6 egg an" I?O in-ibition

































-tt2@99,,,.nbi.n#.ni-.go92&be"917)03770 o % in-ibitors "erease I?O an" Tregs

-tt2@99,,,.-in"a,i.o9o&rna#s9ea9%01%9(013769 interesting one abo&t &sing ist#etoe in G8' b$ "o,nreg&#ating G8' genes an" i2roing N4 e## G8' e## #$sis.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%*%(6**9 "is&sses targeting IL:6B:: rea## t-at ino is

a goo" IL:6 an" IL6 ree2tor in-ibitor

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)(37%*19 "is&sses inter#e&=ins in G8' !,e## IL:6

an" IL1beta

-tt2@99,,,.nbi.n#.ni-.go92&be"9111/370(9 IL:6 as a target in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%6(3)%3( interesting one on obo of #&teo#in an" si#ibinin:::

sees t-e$ in-ibit a&to2-ag$

-tt2@99,,,.nbi.n#.ni-.go92&be"9%/3(03*6 "is&sses &se of obo of arseni trioi"e an"

etforin !interesting t-at it entions t-at etforin easi#$ rosses t-e 888. T-e obo in"&e"a&to2-ag$ an" a2o2tosis in G8' e##s.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)6(1(*) effets of reseratro# on g#ioa ste e##s.

It 2roote" nanog s&22ression ia 2roteosoa# "egra"ation. &st -ae to see if it rosses t-e 888.A#so -e#2s stabi#i;e t-e 888 :::so "ont ,ant t-at as ,i## a=e -ar"er to get ot-er t-ings aross it.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%()*%6)3 a=es refeene to t-e IL:6 iss&e in G8' !it is a

2rob#e B so a$be e2iso"i ino$#ine after % ont-s::: b&t ino an i2air transigration of

ne&tro2-i#s aross 888 B so rea##$ -ae to be aref&# ,it- ino:::i t-in= tiing ,i## be eer$t-ing ,it- ino$#ine.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)*33%61 a nie one on t-e &se of ATRA

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/(7))309 "is&sses t-e &se of obo of "is&#fira an"

ritonair to in-ibit IL:1* in G8' Q


http://www.hindawi.com/journals/ecam/2012/501796/














http://www.hindawi.com/journals/ecam/2012/501796/












-tt2@99,,,.nbi.n#.ni-.go92&be"9%%(6//%) "is&sses a trio of a2to2ri#9"is&#fira9nefinair to

in-ibit G8' 2% an" 27 ::::,e## ino$#ine is a rea##$ goo" 2% an" 27 an" i#6 in-ibitor

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/))*/**9 "is&sses interstitia# treatent for G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"91071//1/ "is&sses t-e e2#oitation of i&ne e-aniss in

t-e treatent of CNS aners.

-tt2@99,,,.nbi.n#.ni-.go92&be"91((*(7*1 "is&sses innate i&ne res2onse in t-e CNS an" itsro#e in G8' i&ne s&rei##ane

-tt2@99,,,.nbi.n#.ni-.go92&be"9177//76) "is&sses t-e e-aniss of #oa# i&noresistane

in G8'

-tt2@99,,,.nbi.n#.ni-.go92&be"9%/(6)6%1 ta#=s abo&t eer$ 6 "a$ etronoi "osing of$#o2-os2-ai"e an" ,-$ t-at t$2e of "osing is essentia# to atiating antit&or innate i&nit$ an"

it ro#e in regression.
















si2#ifie" agent #ist @

1. s&#f&ro2-ane /g bi"%. etforin r 3(0g "ai#$

). e#ebre %00g bi" 1 ont- t-en "ai#$.

/. ieti"ine *00g bi" % ont-s t-en "ai#$(. 1B) 1:6 beta g#&an %000g bi" + a$be a#ternate ,it- t-e 'aita=e '? fration g#&an<

6. e#atonin 6g > -s B ;$rte 10 g at be"tie

3. tadalafil %0g on t&es"a$ A' an" t-&rs"a$ P' eer$ ot-er ,ee= 1$r ). minocycline -1**mg !id + 1 yr then daily

,. sunitini! -*mg daily + "ee's every 6 month + / yrs then / "ee' per yr

1*. 0orafeni! **mg !id + 1 month every 6 months + / yrs then / "ee's per yr

S%ortest most benign list o" agents t%at 'might< do t%e ob.

. 3imetidine !!mg dail#

/. 45 12 beta glucan ;!!mg dail# -&C!!mg vitamin 3 "or C da#s&mont%

5. 3itrulline C!mg dail#

;. 3elebre* ;!!mg dail# (-it% t%e sul"urop%ane$

C. Lipoic acid 2!!mg at 0S and AM(-it% one b1comple* dail#$

2. Minoc#cline !!mg dail# M1T%( start / mont% a"ter start t%e cimetidine$

. Tadala"il Cmg dail#

. Sul"urop%ane 2!mg dail#

E. 9altre*one ;.Cmg at bedtime(take -it% t%e lipoic acid$

T-e agents &n"er#ine" an" in ita#is are for e2iso"i &se on#$.T-e ot-ers are for "ai#$ &se. In#&"e lipoic acid and luteolin for t-eir abi#it$ to "erease IL/ an" IL1)

#ee#s. IL/ an" IL 1) 2#a$ ro#es in '?SC atiation an" i&nos&22ression.

If nee" a "i&reti it s-o&#" be ai#ori"e. +a#ternatie RNA s2#iing agent NO FRCTOSE OR HIGH FRCTOSE CORN SYRP CONTAINING FOO?S.

NO 8ISPHENOL:A E5POSRE + no t-era# reei2ts or "&2#iate -e=sB 2#asti or a#&in& "rin=

ans or bott#esB no fragranes B no ge# t$2e "eo"orantsB no eating on ANY 2#asti foo" ontainers Bnoso&2 ans B no 2roesse" foo"sB on#$ &se B:A "ree #otions an" s-a2oosB s#ee2 in complete "ar=ness.

(ma*imie use o" celebre* "or pain control be"ore adding an# opioid$

Faorite "rin= bre,e" green tea +-ina 9a2an t$2e "ran= ,ar an" s#o, oer )0 in&tes eer$ "a$

Faorite sna= is broo#i s2ro&ts.+ #ot of s&#f&ro2-ane it t-ese

Faorite ints are Green tea ints or Green tea g& for t-e egg.

3A9<T =S) T0IS I9 A98 T6A9S:LA9T :ATI)9T AS IT 7O=LD

3A=S) A9 A3=T) 6)>)3TIO9 )?)9T.



Consi"eration is gien to &sing ATRA +a## trans retinoi ai" at soe 2oint to a##o, t-e '?SCs to

o2#ete t-eir at&ration an" t-en beoe assets in t-e anti t&or res2onse instea" of #iabi#ities to t-e

a&se b&t ATA6A %as LOTS o" ver# nast# adverse e""ects.

E5PLANATION OF AGENTS

protocol has never been used in humans and is so hypothetical at this point in time.

8e#o, is a brief e2#anation of t-e ain effets of t-e agents . T-e e2#anations of t-e e-aniss

-ae been rea##$ si2#ifie" b&t s-o&#" s&ffie to affor" a basi &n"erstan"ing of ,-$ t-e agents ,ere

se#ete" or are being onsi"ere". A "ee2er &n"erstan"ing an be obtaine" b$ rea"ing t-ro&g- a## of t-ereferenes.

Metformin: 'etforin o"&#ates an$ signa#ing s$stes in aner e##s. Fro an i&ne

stan"2ointB it ,i## enfore e2ression of 'HC I s&rfae antigens in t&or e##s. T&or e##s ,i## aoi""etetion fro $totoi T e##s b$ retrating t-eir 'HC I antigens fro t-eir s&rfae. 8$ enforing

re:e2ression of t-ose 'HC I antigens on t-e e## s&rfaeB etforin s-o&#" -e#2 to a=e t-e t&or

e## ore isib#e to t-e $totoi T e##s. 'etforin ,it- s&#f&ro2-ane s-o&#" "o,nreg&#ate NTs$stes in aner ste e##s an" a&se t-e to 2eranent#$ #ose se#f rene,a# abi#ities. T-e

s&#f&ro2-ane ,i## a#so i2air PGE % 2ro"&tion in '?SCs. Prob#e is fin"ing a 2&re so&re of

s&#f&ro2-ane. T-at is t-e on#$ reason it is not in#&"e" in t-e 2rotoo#.

Cimetidine: Cieti"ine at a "ose of *00g ,i## res&#t in an inrease in t-e n&ber of Nat&ra#

4i##er e##s an" inrease t-e #ee# of inter#e&=in:%. Cieti"ine ,i## a&se t-e "eat- of $e#oi" "erie"

s&22ressor e##s ia a2o2toti e## "eat-. '$e#oi" "erie" s&22ressor e##s are a rea# 2rob#e bea&se

t-e$ are a signifiant 2#a$er in t&or "rien i&no:s&bersion an" i&no:easion an" i2air

Nat&ra# 4i##er e## f&ntions. T-e$ an ao&nt for &2 to /0 of t-e t&or ass. T-e$ a#so 2#a$ a#ea"ing ro#e in t-e estab#is-ent of 2reetastati sites basia##$ b&i#"ing a nest for t&or e##s B t-en

2&tting a ,e#oe -oe beaon in t-at 2reetastati nest to attrat t&or e##s t-at a$ be ir&#ating

in t-e b#oo" . T-e ore $e#oi" "erie" s&22ressor e##s in t-e 2atient ,it- so#i" t&orB t-e ,orse t-e 2rognosisB so an$tie ,e an inatiate or =i## t-ese t$2es of e##sB ,e s-o&#" ta=e t-e o22ort&nit$.

Cieti"ine ,i## a#so "erease t-e rena# t&b&#e seretion of etforin an" inrease etforin 2#asa#ee#s fro %( to (0 . T-is a=es for a nie ,a$ to inrease etforin #ee#s ,it-o&t an inrease inGI si"e effets fro ora# etforin. Cieti"ine is a#so s$nergisti ,it- Leaiso#e .



Celebrex: Ce#ebre ,i## res&#t in a "erease in $e#oi" "erie" s&22ressor e##s of a## s&bt$2es. T-e

en" res&#t of e#ebre s-o&#" be -ig-#$ atiate" $totoi T e##s an" better "en"riti e## base"

i&not-era2$ bea&se of re"&e" $e#oi" "erie" s&22ressor e## e2ansion.

Le#amisole: Leaiso#es ations in aner are &#ti2#e an" rea##$ o2#e. S&ffie it to sa$ t-at

fro

an i&noo"&#ator$ stan"2ointB It ,i## 2artia##$ reert t-e aner "rien i&no:s&bersion of t-ei&ne s$ste fro a TH:% "oinant i&ne s$ste to,ar"s t-e reinstateent of a TH:1 "oinant

i&ne sit&ation. T-e i&noo"&#ator$ effets of Leaiso#e are s$nergisti ,it- t-ose of

Cieti"ine.

Beta Glucan: 8eta g#&an s-o&#" a&se a reinstateent of a TH:1 "oinant i&ne s$ste . Its

ations are o2#e. A si2#e ,a$ to t-in= of its ations is to &n"erstan" t-at it re2rogras t-e

i&ne s$ste to e2ress strong an" 2ro#onge" TH:1 s$ste attrib&tes to -e#2 ,it- $totoi T e##an" "en"riti e## f&ntions B o"&#ates seera# =e$ inter#e&=ins an" rea##$ "ereases t-e n&bers of

$e#oi" "erie" s&22ressor e##s. It is not absorbe" B b&t interats ,it- t-e 2e$ers 2at-s aro2-ages

in t-e sa## intestine an" t-ose aro2-ages 2i= &2 soe of t-e g#&an 2arti#esB 2roess t-e an"

t-en -an" t-e off B#i=e a batonB to ot-er i&ne e##sB ,-o t-en notif$ t-e rest of t-e re#eant i&netiss&es to re2rogra t-ings to a TH:1 state B bea&se t-e$ fear t-e beta g#&an is t-e -era#" eent to a

nast$ f&nga# infetion an" t-e -&an i&ne s$ste -as eo#e" to -ate f&nga# infetions B it is &st a-a22$ ai"ent t-at t-e sae s$ste +TH:1 B t-at "ea#s ,e## ,it- f&nga# infetions a#so "ea#s ,e## ,it-t&ors. T-e 1B) 1:6 e2#ains t-e bin"ing an" bran-ing traits of f&nga# or $east beta g#&ans .T-e ore

o2#e t-e bran-ing traitsB t-e better fro an i&no:o"&#ator$ stan"2oint. 8ateria# beta

g#&ans -ae 1B/ instea" of 1B) . T-e Jitain C is in#&"e" in t-e 2rotoo# bea&se it -as a s$nergistieffet ,it- t-e 8eta g#&an in re2rograing t-e i&ne s$ste. If one -a" t-e I' ersion of

betag#&an :::t-at ,o&#" be fine to &se + I t-in= a$o got t-eirs fro 8iot-era in innesota

t$in6 You need robust TH1 attributes to respond to any monoclonal

antibody in any useful way'

-tt2@99,,,.biot-era.o9inestors9fatKs-eet.-t# t-is &st -as a""ress info on biot-era ! I t-in=B

'a$o got t-eir inetab#e for of PGG1B) 1:6 beta g#&an for &se in t-eir CLL ono#ona# st&"$ fro

biot-era o&t of Egan 'N.



5ipyridamole: ?i2$ri"ao#e ,i## i2air t-e abi#it$ of t-e t&or e##s to -i"e fro t-e Nat&ra#

4i##er e##s b$ oating t-ese#es ,it- 2#ate#ets. T&or e##s B,-en in t-e b#oo" strea #i=e to #oa=t-ese#es ,it- 2#ate#ets to aoi" -aing t-eir antigens "etete" b$ t-e i&ne s$ste. T-e

"i2$ri"ao#e 2artia##$ reoes t-is abi#it$ b$ o"&#ating seera# signa#ing s$stes on t-e 2#ate#ets so

t-e$ no #onger a"-ere to t-e t&or e##s. T-is Bt-enB e2oses t-e t&or e##s s&rfae antigens. It ,i##a#so "erease t-e n&ber of t&or assoiate" aro2-ages an" $e#oi" "erie" s&22ressor e##s

infi#trating t-e 2riar$ t&or . It is notab#e t-at t-e -ig-er t-e 2#ate#et o&nts in an$ so#i" t&or 2atientsB t-e ,orse t-e o&toe.

Minocycline: 'ino$#ine ,i## in-ibit inter#e&=in:6 an" "o,n reg&#ate t-e e2ression of t-e

inter#e&=in:6 ree2tor. It a#so ,i## in-ibit atrieta##o2roteinase:% an" 7. T&ors &se ''P% an"

''P7 to en-ane inasion into tiss&es ,-en estab#is-ing etastati sites. Inter#e&=in:6 is t-e

instigator of an$ an$ 2rob#es in aner 2atients B fro a-eia to i&no:s&bersion.Inter#e&=in:6 ,i## b#&nt t-e TH:1 i&ne res2onse an" en-ane t-e TH:% i&ne res2onse in so#i"

t&or 2atientsB so an$tie ,e an in-ibit inter#e&=in:6 in t-e aner 2atient B ,e s-o&#" ta=e t-e

o22ort&nit$. 'ino$#ine -as an$ ot-er ore o2#e ations B b&t fro an i&ne stan"2oint B t-eaboe is a goo" s&ar$. I#:6 an" '?SCs are t-e ain "riers of a-eia in $ o2inion an" so

ino$#ine at 100g >"B s-o&#" n&##if$ t-e effet of IL:6 on a-eiaB ,-i#e t-e ot-er '?SC

"e2#eting agents s-o&#" "ea# nie#$ ,it- t-e '?SC iss&es as t-e$ a22#$ to a-eia.

7!3luorouracil: (:F ,i## =i## $e#oi" "erie" s&22ressor e##s . n#ess &sing it at f&## "ose for

fora##$ treating a anerB #o, "ose is reoen"e" for t-e 2rotoo#. 'a$be &sing it for 3 "a$s eer$ont- ,o&#" be reasonab#e . 'ino$#ine s-o&#"U 2reent an$ (:F re#ate" -eobrain.

Sunitinib ,i## a&se a "rasti re"&tion in '?SCs

Sora"enib ,i## a&se a "erease in '?SCs an" a#so i2airs aner ste e##s.

Monoclonal 0ntibody: A 'ono#ona# Antibo"$ ,i## -e#2 to ar= t-e t&or e##s an" s-o&#"

t-en -e#2to in"&e a2o2tosis in t&or e##s. T-e 2rotoo# re8uires t&or e## a2o2tosis in or"er to

be effetie.-i- ono#ona# to &se ,i## "e2en" on t-e 2arti&#ar t&or ino#e". If no ono#ona#

is to be fo&n" for t-e 2arti&#ar t&orB t-en &sing si#t&iab against inter#e&=in:6B an" "e2en"ing on

ra"iation or fora# -eot-era2$ to in"&e a2o2tosis s-o&#" ,or= . Regar"ing t-e iss&e ofono#ona#s not being er$ effetie I t-in= t-e ono#ona#s ,i## be &- &- ore effetie ,-en

&se" in t-e ontet of t-is 2rotoo# bea&se of t-e t-e i&noo"&#ating effets of t-e ario&s agents.

For 2anreati anerB t-e ono#ona# s-o&#" be Here2tin if HER% 2os+30 of 2anreati aners are Her% 2os



Citrulline: selecti#ely s-o&#" -e#2 2roi"e arginine to T e##s ia arginos&inate s$nt-ase an"

-e#2s aoi" arginine "e2#etion in"&e" i&nos&2ression of t-e $totoi t e##s. T-e C$steine s-o&#"

-e#2 2reent '?SC in"&e" "e2#etion of $steine an" s-o&#" i2roe abi#it$ to atiate "* e##s.

Gemcitabine: Geitabine is an agent t-at =i##s $e#oi" "erie" s&22ressor e##s. 'AY a#so -ae

2otentia# to a#so se#et for aner ste e##s in soe aners<+::nee" ore st&"iesB so if &se t-is one

t-en 2robab#$ s-o&#" a#so be &sing etforin an" s&#f&ro2-ane9sorafenib in obination ,it-

geitabine as t-at obination s-o&#" =i## bot- "ifferentiate" t&or e##s an" aner ste e##sB or at

#east a&se t-e to #ose se#f rene,a# ,-en t-e$ #eae t-e esen-$a# state as a res&#t of o"&#ationof NT s$stes. or use in this protocol B as an agent to "erease $e#oi" "erie" s&22ressor e##sB

one ,o&#" -ae to be aref&# . On#$ e2iso"i &se ,o&#" be a"ise". 'ore inforation is nee"e" ,it-

t-is one. C&rrent#$ it is not in#&"e" in t-e 2rotoo#. If t-e$ are a#rea"$ on it for t-e aner t-en t-etoiit$ to $e#oi" "erie" s&22ressor e##s is &st a er$ nie si"e effet. T-e s&#f&ro2-ane s-o&#"

a#so in-ibit PGE% 2ro"&tion in '?SCsB an" i2air t-eir f&ntions.

Tadalafil: Ta"a#afi# ,i## in-ibit arginase:1 ,it-in t-e $e#oi" "erie" s&22ressor e## an" i2air its

f&ntion. Arginase:1 "e2#etes arginine an" in"&es arginine "e2#ete" i&nos&2ression of t-e T:e##s.

4itamin 5: Jitain is a o2#e i&noo"&#ator$ agent . It is a#so a aster reg&#ator of $

signa#ing s$stes. It is a#so =e$ 2#a$er in atiation of T:e##s. &st a=ing ertain it is ,it- in t-enora# range s-o&#" s&ffie. Jitain ? ations are o2#e . e "o not ,ant 2rofo&n" "efiien$ state

bea&se of $ iss&es B b&t t-ere a#so is "ata t-at rob&st #ee#s a$ s-ift t-e i&ne s$ste to,ar"

t-e TH% s$ste an" t-at ,o&#" be &n"esirab#e in t-is 2rotoo# as ,e 2refer strong TH1 attrib&tes in t-e 2rotoo#.

0bstain from Bisp$enol!0 / MG/ Met$ylparabens and 2arabens and

3ructose: 8is2-eno#:A an"

'SG ,i## s-ift t-e i&ne s$ste to,ar"s TH:% e2ression. TH:% s-ifting is one of t-ei&nos&bersion too#s so#i" t&ors &se to aoi" "etetion. 'et-$#2arabens an" Parabens ,i##

inrease e2ression of 'tor signa#ing s$ste an" i2air t-e e2ression of P() signa#ing s$ste T,o

t-ings one ,o&#" never ,ant to "o in a so#i" t&or bea&se it ,i## a=e t-e t&or ore aggressie.8is2-eno#:A an" 'et-$#2arabens an" Parabens are a#so enoestrogeni agents an" so one o&#"

oeroe t-e 2rotetion of antiestrogeni t-era2ies ,it- een o"erate e2os&res. Fr&tose is t-es&gar t&ors 2refer. T-e$ gro, faster ,-en e2ose" to fr&tose. For t-e 2rotoo#B &st ass&e

8is2-eno#:A is 2resent in a## 2#asti an" eta# an" a#&in& foo" an" beerage ontainers an" on a##t-era# reei2ts an" "&2#iate -e=s an" in ost -an" #otions+&n#ess it sa$s b2a free an" abstain fro

e2os&re to t-ese t-ings. A#soB for t-e 2rotoo#B si2#$ ass&e t-at et-$#2arabens an" 2arabens are

in a## s-a2oos9osetis an" -air on"itioner agents an" ge# base" &n"er ar "eo"orants &n#ess t-e bott#e states ot-er,ise.



)iclosamide: Ni#osai"e ,i## 2robab#$ be a""e" to t-e 2rotoo# an" its effets are >&ite o2#e

an" rea##$ benefiia#B b&t nee" ore inforation on it re#ating to ser& #ee#s ,it-o&t o"if$ing it,it- 2-os2-ate to i2roe bioaai#abi#it$. T-ere is soe "ata t-at i2#ies t-e effets of ni#osai"e

are a-ieab#e at nanoo#ar onentrations an" ,it- a % gra ora# "ose of t-e non2-os2-ate o"ifie"

"r&g B one an a-iee iroo#ar onentrations. If t-at is t-e ase in -&ans t-en a""ing it to t-e 2rotoo# is a si2#e -oie bea&se of t-e effets on STAT:) an" ot-er signa#ing s$stes.

If it t&rns o&t t-at t-e 2-os2-ate o"ifie" ni#osai"e o#e&#e is nee"e" to i2roe bioaai#abi#it$ toa-iee t-e "esire" effets t-en #inia# aai#abi#it$ beoes a 2rob#e bea&se t-en one nee"s a

2-arae&tia# #ab to a=e t-e st&ff.

Lipoic acid and luteolin: T-ese in-ibit IL/ an" IL1) . T-ese t,o inter#e&=ins a&se a #ot of

2rob#es in so#i" t&or -osts.Sti## t-in=ing abo&t ,-at "ose to &se..+"ose for #i2oi ai" ,o&#" be 600g bi"< an" if &se #i2oi ai"

t-en nee" to in#&"e a b:o2#e itain .



Refs

-tt2@99#inanerres.aaro&rna#s.org9ontent91393916/(9T1.e2ansion.-t# nie #ist of agents an"

e-aniss for interfering ,it- '?SCs

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)/%/0%/ beta g#&an effet on '?SC:: it drasticall# "o,nreg&#ate" '?SCs

-tt2@99,,,.i&no#.org9ontent917%91KS&22#eent91)*.)% beta g#&an o"&#ates '?SCs

-tt2@99,,,.b#oo"o&rna#.org9ontent91139%(96*%(<sso:-e=e"1 "is&sses beta g#&an effet oni&ne s$ste !es2 2arti&#ate beta g#&an

[email protected]&trition.org9ontent9*09191(/.f&## se#eni& effet on i&ne s$ste in 2o#io :::it "oessii#ar t-ings in -i ::::s&s2et sae t-ing in aner.

-tt2@99,,,.nbi.n#.ni-.go92&be"97((*3%7 se#eni& an" i&ne f&ntion

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)301**%9 goo" one on '?SCs

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%*100*(9 "is&sses ai#ori"e effet on '?SC

-tt2@99,,,.nbi.n#.ni-.go92&be"936)*%// se#eni& restores age re#ate" i&ne e## f&ntion

::f$i !it inreases I#% ree2tors.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)%%0030 ieti"ine =i##s '?SCs ia as2ase re#ate" "eat- !so t-at is ,-$ ino$#ine is gonna be e2iso"i

-tt2@99,,,.nbi.n#.ni-.go92&be"9%%(/677/ nie one on reg&#ation of '?SC "eat- Q a#so 2ointsto ,-$ nee" ino$#ine in soe for to in-ibit P)* 'a2= s$ste.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)10731%9 s-o,s t-e reta#iator$ re#ations-i2 bet,een

http://clincancerres.aacrjournals.org/content/17/7/1645/T1.expansion.html


http://www.jimmunol.org/content/192/1_Supplement/138.32

http://www.bloodjournal.org/content/117/25/6825?sso-checked=1

http://ajcn.nutrition.org/content/80/1/154.full











http://clincancerres.aacrjournals.org/content/17/7/1645/T1.expansion.html


http://www.jimmunol.org/content/192/1_Supplement/138.32

http://www.bloodjournal.org/content/117/25/6825?sso-checked=1

http://ajcn.nutrition.org/content/80/1/154.full










'?SCs an" atiate" T:e##s::: ie '?SCs in-ibit t:e## atiation B b&t one atiate"B t:e##s ,i## =i##

'?SCs ia fas:fas# +rea## ieti"ine =i##s '?SCs ia &2reg&#ation of fas9fas# s$stes......

..so a$be inrease" '?SC =i##ing ,it- ieti"ine an" atiate" T e##s so maybe just periodic

minocycline so as not to interfere with apoptosis.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)6766*)9 e2#ains -o, '?SCs &se 8CL:5L

o"&#ation to "o,nreg&#ate fas to aoi" CTL =i##ing efforts::: #eer #itt#e b&ggers !arent t-e$.on"er if -i &ses soet-ing sii#ar. T-ere is an agent to "erease b# # ::: ,i## -ae to retriee t-e

info.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)0131)7 PGE % effet on '?SC

-tt2@99,,,.nbi.n#.ni-.go92&be"9%/36%60/ effet of t-eanine on o% in-ibition in "en"riti e##s

!it "erease" o% at transri2tiona# an" trans#ationa# #ee#. It 2roote" t-e seretion of IL:1%

-tt2@99,,,.nbi.n#.ni-.go92&be"91%6)1(7) so goo" to 2reent o % in "en"riti e##s

-tt2@99,,,.nbi.n#.ni-.go92&be"9%1)//13/ t-eanine as a ast e## stabi#i;er

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)%13)(%9 PGE% an" CO5% for 2ositie fee"ba=

#oo2 to re"iret "en"riti e##s "ifferentiation to for stab#e '?SC 2o2&#ations...

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%*%*)/79 '?SC as i&ne s$ste reg&#ators

-tt2@99,,,.nbi.n#.ni-.go92&be"91%7036139 effet of ATRA on '?SCs

-tt2@99,,,.nbi.n#.ni-.go92&be"9170**0// ATRA a##o,s '?SCs to o2#ete t-eir"ifferentiation 2roess an" beoe assets to t-e s$ste.

-tt2@99,,,.nbi.n#.ni-.go92&be"917%36%*6 s&nitinib REALLY "e2#etes '?SCs

-tt2@99,,,.nbi.n#.ni-.go92&be"91*7%3)10 s&nitinib "erease" tregs




























-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)311%)/9 effet of sorafenib on '?SCs an" tregs

-tt2@99,,,.2#osone.org9arti#e9info)A"oi%F10.1)31%Fo&rna#.2one.0060*13 "is&ssesino$#ine effet on IL:6:: so ,e nee" ino$#ine a&se it "oes a #ot of t-ings to i2air t-e

foration of '?SCs B an" IL:6 a&ses &st SO 'ANY 2robs in anerBB 8T it an a#so i2air t-e

=i##ing of '?SCs bea&se it is antia2o2toti agent !so "o&b#e e"ge s,or". Hene e2iso"i &se.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%7)7((%9 goo" one t-e effets of o % in-ibition on

'?SC n&bers ::: e#ebre "erease" '?SCs of a## s&bt$2es.

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)0131)6 "is&sses '?SCs

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)0131)( ore on '?SCs f&ntions in aner

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)(17%*%9 #:arginine etabo#is b$ '?SCs

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)0131/) '?SC e"iate" i&nos&22ression

-tt2@99,,,.nbi.n#.ni-.go92&be"9%)0131)6 i&nos&22ressie '?SC ations

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)301**%9 "is&sses t-e o2#e re#ations-i2 bet,een

'?SCs an" T:e##s

-tt2@99,,,.nbi.n#.ni-.go92&be"911)1))369 e-aniss of '?SC i&ne "$sf&ntion

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/017*7(9 a nie one on t-e ario&s ,a$s to ess ,it-

'?SCs::: this is a really good article


http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0060817



























-tt2@99,,,.nbi.n#.ni-.go92&be"9%0)**37(9 e2#ains -o, ( F =i##s '?SCs

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C))7*0%/9 s-o,s t-at "ereasing '?SC "oes -e#2

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)107%%69 goo" one on '?SC an" t&or esa2e

e-aniss::::rea## t-at &2to /0 2erent of t&or ass an be '?SCs

-tt2@99,,,.nbi.n#.ni-.go92&be"9%1(6*7)/ anot-er goo" one on (:F

-tt2@99,,,.2#osone.org9arti#e9info)A"oi%F10.1)31%Fo&rna#.2one.00/73// s&#f&ro2-ane

in-ibits PGE% 2ro"&tion in '?SCs::: #oo= ,-at it "i" to irosoa# 2rostag#an"in Es$nt-ase.....>&ite rear=ab#e ...es2 ,-en onsi"er obining SFN ,it- a o % in-ibitor an" an

arginase:1 in-ibitor...... s-o&#" be ab#e to rea##$ -a2er '?SC interna# f&ntions.

[email protected]&2ress.org9ontent9%0)91%9%671 ta"a#afi# ats as arginase:1 in-ibitor in '?SCs

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/)6*1()9 goo" one '?SC as a target

-tt2@99,,,.nbi.n#.ni-.go92&be"9106(36339 I t-in= it s&22orts t-e t-in=ing t-at ,eat-er ets or

not :::got to reoe t-e t&or if at a## 2ossib#e Q...it ,i## -e#2 i2air t-e t&or "rieni&nos&bersion ! rea## t-at ieti"ine at *00g bi" ,i## 2reent 2ost s&rger$ i&nos&22ression

an" s&rger$ in"&e" TH% s-ifting eents.

-tt2@99,,,.nbi.n#.ni-.go92&be"91()1)7%*9 "is&sses arginase:1 f&ntions in i&nos&bersion

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C/0)%7/09 ta#=s abo&t t-e etabo#i as2ets of '?SCs

an" T e##s.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%*0(0(39<re2ort#assi "is&sses t-e $steine

"e2#etion b$ '?SCs::: ig-t $steine s&22#eentation -e#2 <








http://jem.rupress.org/content/203/12/2691













http://jem.rupress.org/content/203/12/2691








-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%6/6/0/9 aino bis2-os2-onates brea=s t-e '?SC

e2ansion iss&e b$ "ereasing ''7

-tt2@99,,,.nbi.n#.ni-.go92&be"913613(*79 rossta#= bet,een '?SC an" aro2-ages s&bert

t-e i&ne s$ste to t-e TH% si"e

-tt2@99,,,.nbi.n#.ni-.go92&be"91(6)/**1 s&22orts t-e t-in=ing t-at TH1 s$ste if -e#2f&# in

reeting estab#is-e" etastati "isease

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C133/)1/9 "is&sses arginine etabo#is b$ #ier itr&##ine aoi"s t-is

-tt2@99n&trition.-ig-,ire.org9ontent91)39691616S.f&## a goo" on itr&##ine9nos9arginine

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C)///*%/9 "is&sses itr&##ine an" arginine etabo#isin $obateria infetions

-tt2@99,,,.nbi.n#.ni-.go92&be"91()/))63 e2#ain ;eta -ain f&ntion an" i2ortane.

-tt2@99,,,.nbi.n#.ni-.go92&be"91((6*%*7 itr&##ine an 2resere T:e## ;eta -ains in arginine

"e2#ete" states. 8asia##$ t-e t:e##s i2ort t-e itr&##ine an" onert it into arginine &sing t-eir

arginos&inate s$nt-ase to oeroe arginine "e2#ete" i&ne s&22ression.&st giing arginine ,i## NOT #ea" to inrease" intracellular arginine #ee#s ! t-at is ,-$ $o& nee" to

gie itr&##ine.

-tt2@99,,,.nbi.n#.ni-.go929arti#es9P'C%%00*039 "is&sses t-e nee" to reert i&ne

to#erane in so#i" t&or













gliobastoma protocol 1c

Documents